Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Academic Study Confounds Latest UK Zytiga Reimbursement Consultation

Executive Summary

Janssen, the Institute of Cancer Research and patient groups have reacted with disappointment to NICE draft guidance recommending that Zytiga should not be funded by England's National Health Service in a subset of prostate cancer patients. But the existence of an academic study has complicated the situation in an unusual way, and Janssen still hopes to steer a path to reimbursement.

You may also be interested in...

Frustration Over English Funding Rejection For Zytiga And A Win For Ledaga

Janssen and UK health technology assessment body NICE are being urged to sit down together and agree a suitable price for using Zytiga as a first-line treatment for advanced prostate cancer.

New Data, Price Discount Finally Sways NICE On Janssen's Zytiga

NICE, the health technology appraisal institute for England and Wales, has at last recommended the use of Janssen's Zytiga (abiraterone) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) before chemotherapy, three months after initially rejecting its use on the publicly funded National Health Service, due to inadequate cost-effectiveness and efficacy data.

Titans Of Pharma 2021: J&J’s Gorsky Tops Big Pharma Remuneration

A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts